diagnosis
Diagnosis should be made on the basis of radiological investigations [magnetic resonance imaging (MRI) and computed tomography (CT) are both useful] and pathomorphological assessment according to the World Health Organization classification from a biopsy, fine needle aspiration or biliary brush cytology. A final pathological diagnosis has to be obtained before any chemotherapy, radiotherapy or other non-surgical oncological therapy, but is not critical for planning surgery in patients with characteristic findings of resectable biliary cancer.
staging
Staging consists of complete history and physical examination, blood counts, liver function tests, chest X-ray, imaging of the abdomen by sonography and CT scan or MRI, endoscopic retrograde or percutaneous transhepatic cholangiography and possibly endoscopic ultrasonography, cholangioscopy and laparoscopy. Upper and lower endoscopy has to be performed in patients with an isolated intrahepatic mass. The staging is to be given according to the TNM 2010 system seperately for gallbladder cancer (Table 1) , intrahepatic cholangiocarcinoma (Table 2a) , perihilar cholangiocarcinoma (Table 2b ) and distal cholangiocarcinoma (Table 2c ). Hilar cholangiocarcinoma (Klatskin's tumor) is clinically staged depending on the involvement of the hepatic ducts according to the Bismuth-Corlette classification, which is presented in Table 3 .
treatment after incidental finding of gallbladder cancer on pathological review
A radical reresection (after a complete staging including laparoscopy demonstrating resectability) is highly recommended for patients with incidental gallbladder carcinoma stage T1b (tumor invades muscle layer) or greater. Patients with T1a tumors (tumor invades lamina propria) do not benefit further from re-resection if the gallbladder was removed intact, and should be observed only [III, B] . treatment after incidental finding of gallbladder cancer at surgery After incidental finding of gallbladder cancer at surgery, staging has to be performed intraoperatively, and extended cholecystecomy including en bloc hepatic resection and lymphadenectomy with or without bile duct excision has to be considered depending on resectability and the expertise of the surgeon.
treatment of resectable tumors
Complete surgical resection is the only potentially curative treatment available. Resection of gallbladder cancer consists of extended cholecystecomy including en bloc hepatic resection and lymphadenectomy (porta hepatis, gastrohepatic ligament, retroduodenal) with or without bile duct excision. Major hepatectomy including caudate lobectomy such as extended right lobe resection with portal vein resection increases resectability and radicality for stage 3 and 4 hilar cholangiocarcinomas and has been associated with higher 5-year survival rates [III, B] . Preoperative transarterial or portal vein embolization increases the remnant liver volume in patients with estimated postresection volumes of <25% and appears to reduce postoperative liver dysfunction. An indication of biliary drainage should be systematically discussed with specialized surgeons before surgery.
Even in patients undergoing aggressive surgery, 5-year survival rates are 5-10% for gallbladder cancer and 10-40% for cholangiocarcinoma.
adjuvant (and additive) therapy
Additive fluorouracil-based chemotherapy has been associated with a small survival benefit after non-curative resection of gallbladder cancer [II, B] . Postoperative treatment after non-curative resection of cholangiocarcinoma remains controversial, and both supportive care and palliative chemotherapy and/or radiotherapy may be taken into consideration.
As both gallbladder and biliary tract neoplasms present a high incidence of local failure after surgical resection, reaching 52%, a locoregional adjuvant treatment may be considered. Several retrospective reports on adjuvant and recently also on neoadjuvant (chemo)radiotherapy suggest survival benefit in both gallbladder and biliary duct cancer, and postoperative chemoirradiation may be considered as an option. Fluorouracil was mostly used for chemoradiotherapy in biliary cancers. Recently concomitant gemcitabine with or without oxaliplatin has shown feasibility with radiotherapy in this disease.
treatment of unresectable tumors
Palliation of jaundice can be accomplished by endoscopic or percutaneous stenting of the biliary tree or by operative biliary-enteric bypass. Urgent biliary drainage and broad- Tis  N0  M0  Stage IA  T1  N0  M0  Stage IB  T2  N0  M0  Stage IIA  T3  N0  M0  Stage IIB  T1  N1  M0  T2  N1  M0  T3  N1  M0  Stage III  T4  Any N  M0  Stage IV Any T Any N M1 activity and good tolerability of gemcitabine with oxaliplatin in biliary cancers. In the past, lacking randomized controlled trials and an accepted standard, 5-fluorouracil or gemcitabine was routinely used. Monotherapy with these agents should be considered in a case where gemcitabine combined with either cisplatin or oxaliplatin is not applicable. Limiting toxicity of cisplatin may be renal or neuronal toxicity, myelosuppression or ototoxicity, whereas sensory neuropathy may be limiting for oxaliplatin. The biologicals erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, have shown clinical activity in biliary cancer in a phase II trial. Due to infrequent grade 3 and 4 adverse effects in patients with this disease, the combination of bevacizumab and erlotinib may be a therapeutic alternative to cytostatic chemotherapy.
Concurrent chemoirradiation is an additional therapeutic option. After years of fluorouracil-based chemoradiotherapy, gemcitabine and oxaliplatin have demonstrated feasibility as concomitant chemotherapy (see adjuvant/additive therapy). High radiation doses delivered by use of brachytherapy boost using iridium-192 may improve local control of disease. Recently, intensity-modulated radiotherapy (IMRT) was shown to allow safe dose escalation to much higher doses compared with 3D-conformal radiotherapy and in this the way for future trials to test the effect of radiotherapy in this disease, as recently shown in a retrospective comparative trial. Neoadjuvant therapy is not a routine option in biliary cancers. However, if restaging in patients with locally advanced disease shows potentially resectable tumors, resection should be considered.
Liver transplantation is indicated under strict research protocols at selected centers, for patients with early stage cholangiocarcinoma and anatomically unresectable lesions, but this approach is experimental and should not be offered outside the scope of clinical trials. Data on photodynamic therapy are slightly more advanced. In cholangiocarcinoma, photodynamic therapy after decompression of the biliary tree has been proved to provide survival benefit in two small randomized trials [II, B] . In patients with a large visible mass on radiographic studies, the effect of photodynamic therapy may be limited and combination with chemotherapy may be considered, although appropriate trials are lacking.
response evaluation
Response evaluation is recommended 3 months after photodynamic therapy by means of cholangiography during routine stent exchange and after two or three cycles (8-12 weeks) of chemotherapy by clinical evaluation, subjective symptom evaluation, blood tests and repeating the initially abnormal radiological or ultrasound examinations. In a phase II trial of palliative chemotherapy in patients with advanced biliary cancer, decreases in SUV(max) on [
18 F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scans after 8 weeks of treatment were associated with disease control and increases in progression-free and overall survival.
follow-up
There is no evidence that regular follow-up after initial therapy may influence the outcome. Follow-up visits after complete resection should be restricted to history and physical examination considering symptoms, nutrition and psychosocial problems. 
